Ptc Therapeutics, INC 8-K filings

PTC Therapeutics announced its selection as the winning bidder to acquire ST-920, a BLA-stage gene therapy for Fabry disease, from Sangamo Therapeutics in a bankruptcy auction.

PTC Therapeutics announced the completion of its private offering of $550 million in 0% Convertible Senior Notes due 2031, with net proceeds intended for general corporate purposes and repurchasing existing convertible notes.

PTC Therapeutics announced the pricing of a $500 million offering of 0% Convertible Senior Notes due 2031, with proceeds intended to refinance existing 2026 notes.

PTC Therapeutics board member Alethia Young has resigned, transitioning into a one-year consulting role with the company.

PTC Therapeutics shareholders re-elected four directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

PTC Therapeutics reported strong Q1 2026 financial results, driven by Sephience, and raised its full-year revenue guidance.

PTC Therapeutics announced positive topline results from the 24-month interim analysis of the PIVOT-HD extension study for votoplam, showing dose-dependent slowing of disease progression in Stage 2 Huntington's disease patients.

PTC Therapeutics, Inc. announced the appointment of Jessica Chutter, a seasoned biotechnology investment banker, to its Board of Directors, effective immediately.

PTC Therapeutics announced strong fourth quarter and full-year 2025 financial results, driven by the successful global launch of Sephience, and provided 2026 financial guidance.

PTC Therapeutics announced the withdrawal of its New Drug Application resubmission for Translarna for nonsense mutation Duchenne muscular dystrophy following negative FDA feedback.

PTC Therapeutics announced preliminary unaudited 2025 financial results, exceeding revenue guidance, and provided 2026 financial guidance, highlighting strong Sephience launch momentum and pipeline advancements.

PTC Therapeutics, Inc. has sold its retained royalty interest in Roche's Evrysdi product to Royalty Pharma for $240 million upfront cash and potential future payments.

PTC Therapeutics reported strong third-quarter 2025 financial results, driven by the successful global launch of Sephience and narrowed full-year revenue guidance.

PTC Therapeutics announced it received a Complete Response Letter from the FDA for its New Drug Application for vatiquinone, indicating a need for an additional study.

PTC Therapeutics, Inc. has agreed to pay up to $750 million to cancel future sales-based payments related to its acquisition of Censa Pharmaceuticals.

PTC Therapeutics announced its second quarter 2025 financial results, highlighted by the European and FDA approvals and global launch of Sephience for PKU, alongside mixed financial performance.

PTC Therapeutics announced FDA approval of Sephience (sepiapterin) for children and adults with sepiapterin-responsive phenylketonuria (PKU), marking a significant milestone for the rare disease community.

PTC Therapeutics, Inc. announced the successful re-election of three Class III directors, the ratification of Ernst & Young LLP as its independent auditor, and the approval of named executive officer compensation at its Annual Meeting held on June 17, 2025.

PTC Therapeutics announces solid Q1 2025 financial results with $190 million in revenue, a positive CHMP opinion for Sephience, and a strong cash position of over $2.0 billion.

PTC Therapeutics announces positive results from its Phase 2 PIVOT-HD study of PTC518 for Huntington's disease, meeting the primary endpoint of reducing blood Huntingtin protein levels and showing favorable safety and tolerability.

The European Commission has decided against renewing the conditional marketing authorization for PTC Therapeutics' Translarna (ataluren) in Europe, impacting the treatment's availability for nonsense mutation Duchenne muscular dystrophy.

PTC Therapeutics announces strong financial results for 2024, exceeding revenue guidance with $807 million and achieving all clinical and regulatory milestones on schedule.

PTC Therapeutics reported preliminary 2024 results exceeding revenue guidance and provided 2025 financial projections, along with key pipeline updates.

PTC Therapeutics has amended its lease agreement, reducing its leased space and adjusting financial obligations.

PTC Therapeutics has entered into a global licensing and collaboration agreement with Novartis for its PTC518 Huntington's disease program, securing a $1 billion upfront payment and potential for up to $1.9 billion in milestones.

PTC Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher for $150 million in cash.

PTC Therapeutics announced strong third-quarter 2024 results, leading to an increase in full-year revenue guidance to $750-800 million and progress on multiple regulatory submissions.

The European Medicines Agency's CHMP has reaffirmed its negative stance on the renewal of Translarna's marketing authorization for Duchenne Muscular Dystrophy, despite contrary evidence and appeals from physicians and patients.

PTC Therapeutics announced its second quarter 2024 financial results, highlighted by strong revenue performance and the submission of NDAs for sepiapterin and Translarna to the FDA.

PTC Therapeutics' Translarna faces a negative opinion from the European Medicines Agency's CHMP regarding its marketing authorization renewal, prompting a request for re-examination.